

Durvalumab

REJECTED

The Expert Committee, after evaluation, declines to list the medicine proposed in the application.
The Model List of Essential Medicines reports reasons that Committee Members have identified for denying listing.

General description

INN	Durvalumab
ATC codes	L01FF03
Medicine type	Biological agent
EML status history	Application rejected in 2023 (TRS 1049) for Other specified malignant neoplasms of bronchus or lung
Therapeutic equivalent for	
Wikipedia	Durvalumab ↗
DrugBank	Durvalumab ↗

Recommendations

Section Immunomodulators

Parenteral > General injections > IV: 120 mg per 2.4 mL in vial; 500 mg per 10 mL in vial

Indications

Other specified malignant neoplasms of bronchus or lung

